seekingalpha.com   Professional Investor Explains His 2 Largest Healthcare Holdings               Jan. 22, 2014 12:48 PM ET                       By Jake King Sarepta Therapeutics (SRPT) had a tumultuous year, reaching an all-time high of $55.00 last October before tumbling to lows under $13.00 when the U.S. FDA suggested that the company would need to run a phase 3 trial of its lead drug cand…